Differential effects of native and oxidatively modified low-density lipoproteins on platelet function

Platelets

Volumn 8, Issue 2-3, 1997, Pages 163-173

  Naseem, K M ^a   Goodall, A H ^a   Bruckdorfer, K R ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROPEROXYARACHIDONIC ACID; APOLIPOPROTEIN B100; FIBRINOGEN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN;

ARTICLE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 0030763132     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537109777438     Document Type: Article

References (53)

1. Steinberg D, Witztum JL. Lipoproteins and athersclerosis: current concepts. JAMA 1990; 264: 3047-51.
2. Rice-Evans C, Bruckdorfer KR. Free radicals, lipoproteins and cardiovascular dysfunction. In Molecular Aspects of Medicine. Oxford: Pergamon Press: vol 13: 1-112.
3. Carvalho AC, Coleman RW, Lees RS. Platelet function in hyperlipoproteinaemia. New Engl J Med 1974; 290: 434-8.
4. 2 formation in Type-II hyperlipoproteinaemic patients. Eur J Clin Invest 1984; 14: 329-33.
5. Aviram M, Brook JG. Characterisation of the effect of plasma lipoproteins on platelet function in vitro. Haemostasis 1983; 13: 344-50.
6. Hassall DG, Owen JS, Bruckdorfer KR. The aggregation of isolated platelets in the presence of lipoproteins and prostacyclin. Biochem J 1983; 416: 43-9.
7. Meraji S, Moore CE, Skinner VO, Bruckdorfer KR. The importance of oxidation or glycosylation of low density lipoproteins in relation to platelet activation. Platelets 1992; 3: 155-62.
8. Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117-24.
9. Cazzolato G, Avogaro P, Bittilo-Bon G. Characterisation of a more negatively charged low density lipoprotein subfraction by ion exchange HPLC. Free Rad Med Biol 1991; 11: 247-53.
10. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Woolff SP. Authentic plasma hydroperoxide measurement in type II diabetes shows elevated levels. Diabetologia 1994; 37: A146.
11. Stringer MD, Gorog PG, Freeman A, Kakkar VV. Lipid peroxides and atherosclerosis. Brit Med J 1989; 298: 218-84.
12. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1969; 194: 927-30.
13. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991; 65: 467-73.
14. Chung BH, Wilkinson T, Geer JC, Segrest PJ. Preparative and quantitative isolation of plasma lipoproteins: rapid single discontinuous density ultracentrifugation in a vertical rotor. J Lipid Res 1980; 21: 284-91.
15. Lowry OH, Rosebrough NJ. Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1949; 193: 265-75.
16. El-Saadani M, Esterbauer H, El-Sayed M, Goher M. Assar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989; 30: 627-32.
17. Buege JA, Aust SD. Microsomal lipid peroxidation. Meth Enzymol 1978; 52: 302-10.
18. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Canad J Biochem Physiol 1959; 37: 911-7.
19. Rice-Evans C, Diplock AT, Symons MCR. Techniques in Free Radical Research. Amsterdam: Elsevier, 1991.
20. Vargas JR, Radomski M, Moncada S. The use of prostacyclin in the separation from plasma and washing of human platelets. Prostaglandins 1983; 23: 929-45.
21. Naseem KM, Bruckdorfer KR. Hydrogen peroxide at low concentrations strongly enhances the inhibitory effect of nitricoxide in platelets Biochem J 1995; 310: 149-53.
22. Friedewald WT, Levy RI. Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
23. Janes SL, Wilson JW, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993; 70: 659-66.
24. Cox AD, Goodall AH. Activation-specific neo-antigens on platelets detected by monoclonal antibodies. In: Albertini A, Lenfant CL, Manucci PM, Sixma JJ, eds. Current Studies in Haematology and Blood Transfusion. Basel: Karger; 1991: 194-9.
25. 2+-induced oxidation. Biochem J 1995; 110: 417-25.
26. Bruckdorfer KR. The effects of plasma lipoproteins on platelet responsiveness and on platelet and vascular prostanoid synthesis. Prostagl, Leukotr Essnl Fatty Acids 1989; 38: 247-54.
27. Malle E, Sattler W. Platelets and the lipoproteins: native, modified and platelet modified lipoproteins. Platelets 1994; 5: 70-83.
28. Bruckdorfer KR. Lipoproteins and platelets. In: Betteridge J, Illingworth R, Shepherd J, eds. Lipoproteins in Health and Disease. Edward Arnold Publishers (in press).
29. Surya II, Gorta G, Akkerman JWN. Arachidonate transfer between platelets and lipoproteins. Thromb Haemost 1992; 68: 719-26.
30. Greis A, Gries M, Wurm H, Kenner T, Ijsseldijk M, Sixma JJ, Kostner GM. Lipoprotein (a) inhibits collagen-induced aggregation of thrombocytes. Arterioscler Thromb Vasc Biol 1996; 16: 648-55.
31. Broijersen A, Wallen NH, Vitols PT, Larsson PT, Hjemdahl P. Autologous low-density lipoprotein enhances platelet aggregation in whole blood as measured in vitro filtragometry. Platelets 1992; 4: 11-19.
32. Broijersen A, Eriksson M, Angeli B, Hjemdahl P. Gemfibrozil enhances platelet activity in patients with combined hyperlipidaemia. Arterioscler Thromb Vasc Biol 1995; 15: 121-7.
33. Andrews HE, Bruckdorfer KR, Dunn RC, Jacobs M. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature 1987; 327: 237-9.
34. Bruckdorfer KR, Naseem KM, Mohammadi B, Chirico S, Ettelaie C, Gleeson A, Young T, Adam JA, Wilbourn B, Skinner VO, Goodall AH, Khan J, Gates SC, Jacobs M. The influence of oxidised lipoproteins, oxidation products and antioxidants on the release of nitric oxide and the response of platelets to nitric oxide. Biofactors 1997; 1: (in press).
35. Broijersen A, Eriksson M, Larsson PT, Beck O, Berglund B, Angeli B, Hjemdahl P. Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia. Eur J Clin Invest 1994; 24: 488-98.
36. Coumar A, Gill JK, Barradas MA, O'Donoghue S, Jeremy JY, Mikhailidis DP. The effect of treatment with simivistatin on platelet function indices in hypercholesterolaemia. J Drug Develop 1991; 4: 79-86.
37. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988; 18: 399-404.
38. Fetkovska N. Platelet activation by low-density lipoprotein and serotonin: Effects of calcium antagonists. J Cardiovasc Pharm 1992; 19(suppl. 3): S25-8.
39. Janes SL, Wilson DW, Cox AD, Chronis NAF, Goodall AH. ADP causes partial degranulation of platelets in the absence of aggregation. Br J Haem 1994; 86: 568-73.
40. 2 Arterioscler Thromb Vasc Biol 1995; 15: 1131-8.
41. Watson AD, Navab M, Harmsa SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BA, Fogelmann AM, Berliner JA. The effects of platelet activating factor-acetyl hydrolase on the formation and actions of minimally oxidised low density lipoprotein. J Clin Invest 1994; 95: 774-82.
42. Hemler ME, Lands WEM. Evidence for a peroxide-initiated free radical mechanism of prostaglandin biosynthesis. J Biol Chem 1980; 225: 6253-60.
43. Hassall D, Desai K, Owen JS, Bruckdorfer KR. Detection of a protein in human membranes which binds low-density lipoproteins. Platelets 1990; 1: 29-35.
44. Kowalska MA, Tuszynski GP, Capuzzi DM. Plasma lipoproteins mediate platelet adhesion. Biochem Biophys Res Comm 1990; 172: 113-8.
45. Koller E, Koller F, Binder BR. Purification and identification of the lipoprotein-binding protein from human blood platelet membrane. J Biol Chem 1989; 264: 12412-8.
46. Pedreno J, Casterllarnau C, Cullare C, Ortin R, Sanchez JL, Llopart R, Gonzalez-Sastre F. Platelet LDL recognises with the same apparent affinity both oxidised and native LDL. Arterioscler Thromb 1994; 14: 401-18.
47. Besterman EEM, Gillett MPT. Inhibition of platelet aggregation. Atherosclerosis 1971; 14: 323-30.
48. Slater TF, Bendetto C, Cheeseman KH, Collins M, Davies MJ, Flatman S, Hayashi M, Hurst JS, McDonald-Gibson RG, Morgan A, Nigam S, Proudfoot K. Free radical and prostaglandin disturbances in cancer. In: Rice-Evans C, ed. Free Radicals, Cell Damage and Disease. London: Richelieu Press. 1976; 57.
49. Aviram M. Modified forms of low density lipoproteins affect platelet aggregation in vitro. Thromb Res 1989; 53: 561-7.
50. Selley ML, McGuiness SA, Jenkin LA, Bartlett MR, Ardlie NG. Effect of 4-hydrox 2,3 nonenal on platelet function. Thromb Haemost 1988; 59: 143-6.
51. Salonen JT, Salonen R, Seppanen K, Rinta-Kiikka S, Kuukka M, Korpela H, Alfthan G, Kantola M, Schalch W. Effects of antioxidant supplementation on platelet function: a randomized pair-matched, placebo-controlled, double-blind trial in men with low antioxidant status. Am J Clin Nutr 1991; 53: 1222-9.
52. Calzada C, Rice-Evans CA, Bruckdorfer KR. The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis 1997; 128: 97-105.
53. Gorog P, Kovacs IB. Lipid peroxidation by activated platelets: a possible link between atherosclerosis and atherogenesis. Atherosclerosis 1995; 115: 121-8.